Shionogi & Co. Ltd
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Osaka, Japan.
Shionogi & Co. Ltd (SGIOF) - Net Assets
Latest net assets as of December 2025: $1.52 Trillion USD
Based on the latest financial reports, Shionogi & Co. Ltd (SGIOF) has net assets worth $1.52 Trillion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.73 Trillion) and total liabilities ($213.79 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.52 Trillion |
| % of Total Assets | 87.64% |
| Annual Growth Rate | 6.74% |
| 5-Year Change | 57.6% |
| 10-Year Change | 165.14% |
| Growth Volatility | 7.04 |
Shionogi & Co. Ltd - Net Assets Trend (1998–2025)
This chart illustrates how Shionogi & Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shionogi & Co. Ltd (1998–2025)
The table below shows the annual net assets of Shionogi & Co. Ltd from 1998 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | $1.36 Trillion | +8.78% |
| 2024-03-31 | $1.25 Trillion | +11.65% |
| 2023-03-31 | $1.12 Trillion | +12.95% |
| 2022-03-31 | $993.28 Billion | +14.89% |
| 2021-03-31 | $864.55 Billion | +13.07% |
| 2020-03-31 | $764.61 Billion | +13.71% |
| 2019-03-31 | $672.43 Billion | +11.17% |
| 2018-03-31 | $604.84 Billion | +14.94% |
| 2017-03-31 | $526.21 Billion | +2.40% |
| 2016-03-31 | $513.88 Billion | +7.31% |
| 2015-03-31 | $478.88 Billion | +1.37% |
| 2014-03-31 | $472.41 Billion | +11.51% |
| 2013-03-31 | $423.63 Billion | +22.02% |
| 2012-03-31 | $347.20 Billion | +5.82% |
| 2011-03-31 | $328.10 Billion | -4.06% |
| 2010-03-31 | $341.98 Billion | +10.28% |
| 2009-03-31 | $310.09 Billion | -9.39% |
| 2008-03-31 | $342.24 Billion | -1.02% |
| 2007-03-31 | $345.75 Billion | +2.47% |
| 2006-03-31 | $337.43 Billion | +12.45% |
| 2005-03-31 | $300.06 Billion | +2.63% |
| 2004-03-31 | $292.39 Billion | +6.32% |
| 2003-03-31 | $275.00 Billion | -2.18% |
| 2002-03-31 | $281.12 Billion | -2.70% |
| 2001-03-31 | $288.92 Billion | +12.16% |
| 2000-03-31 | $257.60 Billion | +6.01% |
| 1999-03-31 | $242.99 Billion | +3.72% |
| 1998-03-31 | $234.28 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shionogi & Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 485.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $1.12 Trillion | 81.92% |
| Common Stock | $21.28 Billion | 1.56% |
| Other Components | $224.92 Billion | 16.51% |
| Total Equity | $1.36 Trillion | 100.00% |
Shionogi & Co. Ltd Competitors by Market Cap
The table below lists competitors of Shionogi & Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Avery Dennison Corp
NYSE:AVY
|
$13.11 Billion |
|
TKO Group Holdings, Inc.
NYSE:TKO
|
$13.13 Billion |
|
NARI Technology Co Ltd
SHG:600406
|
$13.14 Billion |
|
Tyler Technologies Inc
NYSE:TYL
|
$13.15 Billion |
|
Alfa Laval AB (publ)
PINK:ALFVF
|
$13.09 Billion |
|
CACI International Inc
NYSE:CACI
|
$13.07 Billion |
|
Wiwynn Corp
TW:6669
|
$13.05 Billion |
|
Hasbro Inc
NASDAQ:HAS
|
$13.05 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shionogi & Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,235,326,000,000 to 1,361,924,000,000, a change of 126,598,000,000 (10.2%).
- Net income of 170,435,000,000 contributed positively to equity growth.
- Dividend payments of 48,698,000,000 reduced retained earnings.
- Share repurchases of 10,000,000 reduced equity.
- Other comprehensive income decreased equity by 271,780,000,000.
- Other factors increased equity by 276,651,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $170.44 Billion | +12.51% |
| Dividends Paid | $48.70 Billion | -3.58% |
| Share Repurchases | $10.00 Million | -0.0% |
| Other Comprehensive Income | $-271.78 Billion | -19.96% |
| Other Changes | $276.65 Billion | +20.31% |
| Total Change | $- | 10.25% |
Book Value vs Market Value Analysis
This analysis compares Shionogi & Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-03-31 | $670.90 | $15.40 | x |
| 1999-03-31 | $691.78 | $15.40 | x |
| 2000-03-31 | $737.81 | $15.40 | x |
| 2001-03-31 | $829.05 | $15.40 | x |
| 2002-03-31 | $811.55 | $15.40 | x |
| 2003-03-31 | $789.65 | $15.40 | x |
| 2004-03-31 | $844.71 | $15.40 | x |
| 2005-03-31 | $868.68 | $15.40 | x |
| 2006-03-31 | $989.78 | $15.40 | x |
| 2007-03-31 | $1014.74 | $15.40 | x |
| 2008-03-31 | $1012.39 | $15.40 | x |
| 2009-03-31 | $924.23 | $15.40 | x |
| 2010-03-31 | $1019.68 | $15.40 | x |
| 2011-03-31 | $979.68 | $15.40 | x |
| 2012-03-31 | $1027.83 | $15.40 | x |
| 2013-03-31 | $1254.33 | $15.40 | x |
| 2014-03-31 | $1398.74 | $15.40 | x |
| 2015-03-31 | $1422.08 | $15.40 | x |
| 2016-03-31 | $1541.90 | $15.40 | x |
| 2017-03-31 | $1594.59 | $15.40 | x |
| 2018-03-31 | $1863.95 | $15.40 | x |
| 2019-03-31 | $2116.85 | $15.40 | x |
| 2020-03-31 | $2473.29 | $15.40 | x |
| 2021-03-31 | $2760.06 | $15.40 | x |
| 2022-03-31 | $3235.18 | $15.40 | x |
| 2023-03-31 | $3693.85 | $15.40 | x |
| 2024-03-31 | $4256.65 | $15.40 | x |
| 2025-03-31 | $4802.32 | $15.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shionogi & Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.51%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 38.89%
- • Asset Turnover: 0.29x
- • Equity Multiplier: 1.13x
- Recent ROE (12.51%) is above the historical average (9.44%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | 4.12% | 2.74% | 0.89x | 1.69x | $-13.63 Billion |
| 1999 | 4.10% | 2.64% | 0.91x | 1.71x | $-14.12 Billion |
| 2000 | 5.04% | 3.21% | 0.90x | 1.73x | $-12.65 Billion |
| 2001 | 4.40% | 3.06% | 0.83x | 1.73x | $-16.06 Billion |
| 2002 | 3.01% | 2.01% | 0.87x | 1.71x | $-19.61 Billion |
| 2003 | 2.15% | 2.07% | 0.77x | 1.35x | $-21.58 Billion |
| 2004 | 0.75% | 1.10% | 0.53x | 1.29x | $-27.01 Billion |
| 2005 | 6.32% | 9.50% | 0.50x | 1.32x | $-11.04 Billion |
| 2006 | 6.74% | 11.58% | 0.46x | 1.27x | $-10.98 Billion |
| 2007 | 5.38% | 9.31% | 0.47x | 1.24x | $-15.95 Billion |
| 2008 | 7.33% | 11.70% | 0.52x | 1.21x | $-9.13 Billion |
| 2009 | 5.06% | 6.88% | 0.45x | 1.62x | $-15.30 Billion |
| 2010 | 11.31% | 13.87% | 0.52x | 1.58x | $4.47 Billion |
| 2011 | 6.10% | 7.09% | 0.54x | 1.59x | $-12.78 Billion |
| 2012 | 7.87% | 10.14% | 0.51x | 1.52x | $-7.33 Billion |
| 2013 | 15.88% | 23.59% | 0.49x | 1.37x | $24.70 Billion |
| 2014 | 8.93% | 14.44% | 0.50x | 1.25x | $-5.03 Billion |
| 2015 | 9.28% | 16.08% | 0.45x | 1.27x | $-3.39 Billion |
| 2016 | 13.08% | 21.51% | 0.48x | 1.25x | $15.71 Billion |
| 2017 | 16.05% | 24.75% | 0.51x | 1.28x | $31.61 Billion |
| 2018 | 18.10% | 31.59% | 0.48x | 1.20x | $48.73 Billion |
| 2019 | 19.87% | 36.50% | 0.47x | 1.17x | $65.96 Billion |
| 2020 | 15.98% | 36.65% | 0.38x | 1.14x | $45.74 Billion |
| 2021 | 13.22% | 37.64% | 0.30x | 1.18x | $27.25 Billion |
| 2022 | 11.70% | 34.07% | 0.29x | 1.18x | $16.62 Billion |
| 2023 | 16.81% | 43.35% | 0.33x | 1.19x | $74.96 Billion |
| 2024 | 13.12% | 37.24% | 0.31x | 1.15x | $38.50 Billion |
| 2025 | 12.51% | 38.89% | 0.29x | 1.13x | $34.24 Billion |
Industry Comparison
This section compares Shionogi & Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shionogi & Co. Ltd (SGIOF) | $1.52 Trillion | 4.12% | 0.14x | $13.10 Billion |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |